Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 15, 2016 (11 years ago)

Insulin

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Firm is recalling all unexpired lots of sterile compounded products after FDA inspection found concerns of lack of sterility assurance.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Insulin, 70/30, 10 mL unit size, refrigerate, This Rx is Compounded, Abbott's Compounding Pharmacy, Berkeley, CA 94705

Drug: Insulin Category: Diabetes Medication

Recalling firm
Abbott's Compounding Pharmacy, Inc.
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0684-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Insulin recalls

See all
Class II · Moderate risk

Myxredlin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0126-12 D-0806-2026
Class II · Moderate risk

Admelog

Lack of Assurance of Sterility: Malformed crimped collar seal

Ongoing Sterility / contamination Sanofi-Aventis U.S. LLC NDC 0024-5926-05 D-0575-2023
Class I · High risk

Insulin Glargine

Labeling: Missing label: Label missing from some prefilled pens.

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-394-71 D-1292-2022
Class I · High risk

Insulin Glargine

Labeling: Missing label on the vial

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-393-80 D-0845-2022

Other recalls by Abbott's Compounding Pharmacy, Inc.

All 2016 recalls
Class II · Moderate risk

papaverine phent

Lack of Assurance of Sterility: Firm is recalling all unexpired lots of sterile compounded products after FDA inspection found concerns of lack of sterility assurance.

Terminated Sterility / contamination Abbott's Compounding Pharmacy, Inc. D-0718-2016
Class II · Moderate risk

testosterone cypionate

Lack of Assurance of Sterility: Firm is recalling all unexpired lots of sterile compounded products after FDA inspection found concerns of lack of sterility assurance.

Terminated Sterility / contamination Abbott's Compounding Pharmacy, Inc. D-0717-2016
Class II · Moderate risk

testosterone cypionate

Lack of Assurance of Sterility: Firm is recalling all unexpired lots of sterile compounded products after FDA inspection found concerns of lack of sterility assurance.

Terminated Sterility / contamination Abbott's Compounding Pharmacy, Inc. D-0716-2016
Class II · Moderate risk

progesterone/testosterone

Lack of Assurance of Sterility: Firm is recalling all unexpired lots of sterile compounded products after FDA inspection found concerns of lack of sterility assurance.

Terminated Sterility / contamination Abbott's Compounding Pharmacy, Inc. D-0715-2016